UNITED ~~STATESSECURITIES~~STATES SECURITIES AND EXCHANGE ~~COMMISSIONWashington,~~ ~~D.C. 20549~~COMMISSION

~~Form~~Washington, D.C. ~~6-K~~20549

~~REPORT~~FORM ~~OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a~~6-~~16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934~~K

~~December~~REPORT 6,OF ~~2022~~FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the

Securities Exchange Act of 1934

December 16, 2022

Commission File Number: 001-36686

Forward Pharma A/S

Østergade 24A, 1st ~~Floor1100 Copenhagen K, Denmark~~ Floor

1100 Copenhagen K, Denmark

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Item 1. ~~Other~~Notice ~~Items~~of Delisting

On December 616, 2022, Forward Pharma A/S ~~issued~~(the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq believes that the Company is a ~~press~~"public shell" ~~release~~pursuant ~~regarding~~to Listing Rule 5101, and that the ~~decision~~continued listing of its securities is no longer warranted. The Company will not appeal this determination. Therefore, the ~~Enlarged~~Company ~~Board~~expects the trading of ~~Appeal~~its American Depositary Shares on The Nasdaq Capital Market to be suspended at the opening of business on December 28, 2022, and that Nasdaq will file a Form 25-NSE with the ~~European~~U.S. Securities and Exchange ~~Patent~~Commission ~~Office~~(the in“SEC”), which will remove the ~~EP2801355~~Company’s ~~petition~~securities ~~for~~from ~~review~~listing and registration on The Nasdaq Stock Market. Additionally, the Company intends to file with the SEC a ~~copy~~Form of15 ~~which~~requesting isthe ~~attached~~suspension ~~hereto~~of asthe ~~Exhibit~~Company’s 99reporting obligations.1.

~~EXHIBIT INDEX~~ SIGNATURE

Exhibit No.		Description
99.1		Press Release dated December 6, 2022

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SIGNATURES

	FORWARD PHARMA A/S


Date: December 19, 2022	By:	/s/ Claus Bo Svendsen
		Name: Claus Bo Svendsen
		Title: Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	FORWARD PHARMA A/S
Date: December 6, 2022	By:	/s/ Claus Bo Svendsen
		Name: Claus Bo Svendsen
		Title: Chief Executive Officer

Filing Compare · Forward Pharma A/S